A newly launched Phase I trial from the University of Oxford illustrates how rapid vaccine trial delivery can move at speed while meeting the same regulatory and safety standards, with clear relevance to outbreak response.
The trial, conducted in Oxford, will assess the safety and immune response of the ChAdOx1 BDBV vaccine candidate in 50 healthy adults aged 18 to 55, with volunteer recruitment now underway. Structurally, this is a conventional Phase I trial. Substantively, it is a step toward the first vaccine against a virus with no approved vaccine or treatment, and reaching this stage at this pace required considerable coordination across multiple partners.
Rapid Vaccine Trial Delivery Starts With Manufacturing Ahead of the Data
The Serum Institute of India (SII) manufactured and stockpiled approximately 620,000 doses of the vaccine candidate in two weeks, supplying 4,000 investigational doses for this trial. This represents vaccine manufacturing scale-up conducted in parallel with early clinical evaluation, rather than after it.
This is a deliberate risk position, not a shortcut. This approach, known as at-risk manufacturing, involves producing and stockpiling doses before Phase I safety data confirms a vaccine’s viability. It is only possible because SII’s role sits within the Coalition for Epidemic Preparedness Innovations’ (CEPI) Vaccine Manufacturing Facility Network, a structure built specifically to pre-position manufacturing capacity before it is needed.
What This Means for Sponsors
For sponsors running an outbreak-context or fast-track programme, the operational lesson is straightforward: manufacturing readiness must be designed into the trial timeline from the outset, not introduced once Phase I data arrives. Committing manufacturing resource ahead of clean safety data carries risk, but the alternative, waiting for that data before scaling production, is consistently the slower path.
Speed Built on Existing Infrastructure, Not Improvisation
The programme reached first-in-human dosing 57 days after the World Health Organisation declared the outbreak a public health emergency of international concern. This pace was not achieved by skipping steps. It rests on the ChAdOx1 platform, the same viral vector technology used in the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved over six million lives during its first year of use.
Why Platform Reuse Matters to a Regulator
Reusing a validated platform removes a substantial amount of technical risk before a trial opens. This point is worth making directly to sponsors weighing platform versus bespoke vaccine approaches for emerging pathogens: familiarity with a vector’s safety profile and manufacturing process is not incidental; it is what makes an accelerated timeline credible to a regulator.
Multi-Partner Clinical Trial Delivery, Not Just the Science
The trial sits within an $8.6 million programme funded by CEPI, spanning the University of Oxford, SII, and further planned studies with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine’s Uganda Research Unit. Africa CDC is also involved. Its Director General, Dr Jean Kaseya, has noted that early-stage trials are not an immediate solution for communities facing the outbreak today, but form part of the wider toolkit for this and future responses. [Placeholder: link to Africa CDC statement/source]
Five Partners, Five Distinct Roles
This layered structure- funder, academic sponsor, manufacturer, in-region research partners, and a continental public health body- is a practical example of multi-partner clinical trial delivery. Each partner addresses a different constraint:
- Funding risk: CEPI
- Scientific leadership: University of Oxford
- Manufacturing scale: Serum Institute of India
- In-country clinical delivery: MRC/Uganda Virus Research Institute and LSHTM Uganda Research Unit
- Regional public health alignment: Africa CDC
How Simbec-Orion Supports Accelerated DeliveryÂ
Simbec-Orion has supported clinical development programmes across rare disease, oncology, and complex early-phase indications for over 27 years, working alongside sponsors who need scientific depth as much as operational speed. If you’re planning a trial where timelines are tight, and the patient population is small, hard to reach, or both, our team can talk through what a realistic delivery plan looks like for your programme. Get in touch to discuss your trial;, our Phase 1 services and early-stage consultancy team are built for exactly this kind of accelerated, high-scrutiny delivery.
Accelerated Vaccine trials Frequently Asked QuestionsÂ
What does ‘at-risk’ manufacturing mean in vaccine trials, and what does it require of a delivery partner?Â
At-risk manufacturing in vaccine trials means producing and stockpiling doses before Phase I safety data confirms the vaccine is viable. It is a deliberate financial and operational risk taken to remove time from the development timeline, as seen in this trial with SII’s 620,000 pre-positioned doses. It requires a manufacturing partner willing to commit capacity ahead of confirmed demand, and a funding structure, in this case CEPI’s Vaccine Manufacturing Facility Network, built specifically to support that kind of commitment.
What capabilities does a CRO need to run an outbreak-context or fast-track vaccine trial?
Beyond standard trial delivery, outbreak-context programmes demand regulatory teams who can manage accelerated review processes, operational structures that can coordinate multiple partners (academic sponsors, manufacturers, in-region research units, and public health bodies) without duplicating effort, and enough platform familiarity to make an accelerated timeline credible to a regulator rather than simply fast. The Bundibugyo trial’s 57-day path from PHEIC declaration to first-in-human dosing reflects all three working together, not any single capability in isolation.
How does reusing a validated vaccine platform affect regulatory timelines?
Reusing a platform with an established safety and manufacturing record, such as ChAdOx1, reduces substantial technical uncertainty before a trial opens. Regulators already have safety and production data from prior use of the platform, which shortens the evidence a new candidate needs to generate from scratch. This is a large part of why platform-based candidates can move to Phase I faster than a fully novel vaccine technology, without lowering the evidential bar for safety.